Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

November is National Alzheimer’s Awareness Month, and the Alzheimer’s Foundation of America (AFA) is encouraging those impacted by Alzheimer’s disease — and their supporters — to wear teal and spread ...

Both of my parents, Ruth and Jim Page Sr., have passed from this life to the next. They were tremendous people who loved each other and their children profoundly. They had many gifts, separately and ...

Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other disorders, that will be used in future clinical trials. The ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia. It most often emerges during a person’s mid-60s or older, although early-onset varieties exist.

There is no cure for Alzheimer’s Disease (AD), but some medications may help reduce the symptoms or slow progression of the disease. As AD progresses, brain cells die and the connections between them ...

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by declining mental abilities that affect a person’s memory, cognition, and personality. It is the most common cause of ...

There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease get diagnosed. It is estimated that there are approximately 44 ...